Pancreatic cancer screening: Difference between revisions
Jump to navigation
Jump to search
| Line 8: | Line 8: | ||
==Screening== | ==Screening== | ||
*In asymptomatic adults who are at average risk, the U.S.P.S.T.F recommends against routine screening for pancreatic cancer due to the lack of mortality benefit. | *In asymptomatic adults who are at average risk, the U.S.P.S.T.F recommends against routine screening for pancreatic cancer due to the lack of mortality benefit. | ||
*In high-risk individuals, with familial pancreatic cancer or in those with genetic syndromes predisposing to pancreatic cancer, screening is suggested. | *In high-risk individuals, with familial pancreatic cancer or in those with genetic syndromes predisposing to pancreatic cancer, screening is suggested. In high- risk groups, screening by endoscopic ultrasound (EUS), magnetic resonance imaging (MRI) and magnetic resonance cholangiopancreatography (MRCP) are recommended. | ||
<ref name="pmid22895395">{{cite journal| author=Poruk KE, Firpo MA, Adler DG, Mulvihill SJ| title=Screening for pancreatic cancer: why, how, and who? | journal=Ann Surg | year= 2013 | volume= 257 | issue= 1 | pages= 17-26 | pmid=22895395 | doi=10.1097/SLA.0b013e31825ffbfb | pmc=4113008 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=22895395 }} </ref> <ref name="pmid21960811">{{cite journal| author=Greer JB, Brand RE| title=Screening for pancreatic cancer: current evidence and future directions. | journal=Gastroenterol Hepatol (N Y) | year= 2007 | volume= 3 | issue= 12 | pages= 929-38 | pmid=21960811 | doi= | pmc=3104195 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=21960811 }} </ref> | |||
*Individuals with the following conditions are also at an increased risk of pancreatic cancer:<ref name="pmid26320426">{{cite journal| author=Goral V| title=Pancreatic Cancer: Pathogenesis and Diagnosis. | journal=Asian Pac J Cancer Prev | year= 2015 | volume= 16 | issue= 14 | pages= 5619-24 | pmid=26320426 | doi= | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=26320426 }} </ref> | *Individuals with the following conditions are also at an increased risk of pancreatic cancer:<ref name="pmid26320426">{{cite journal| author=Goral V| title=Pancreatic Cancer: Pathogenesis and Diagnosis. | journal=Asian Pac J Cancer Prev | year= 2015 | volume= 16 | issue= 14 | pages= 5619-24 | pmid=26320426 | doi= | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=26320426 }} </ref> | ||
Revision as of 18:30, 15 November 2017
|
Pancreatic cancer Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Pancreatic cancer screening On the Web |
|
American Roentgen Ray Society Images of Pancreatic cancer screening |
|
Risk calculators and risk factors for Pancreatic cancer screening |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]Associate Editor(s)-in-Chief: Aravind Reddy Kothagadi M.B.B.S[2]
Overview
In asymptomatic adults who are at average risk, the U.S.P.S.T.F recommends against routine screening for pancreatic cancer due to the lack of mortality benefit. In high-risk individuals, with familial pancreatic cancer or in those with genetic syndromes predisposing to pancreatic cancer, screening is suggested. In high- risk groups, screening by endoscopic ultrasound (EUS), magnetic resonance imaging (MRI) and magnetic resonance cholangiopancreatography (MRCP) are recommended.
Screening
- In asymptomatic adults who are at average risk, the U.S.P.S.T.F recommends against routine screening for pancreatic cancer due to the lack of mortality benefit.
- In high-risk individuals, with familial pancreatic cancer or in those with genetic syndromes predisposing to pancreatic cancer, screening is suggested. In high- risk groups, screening by endoscopic ultrasound (EUS), magnetic resonance imaging (MRI) and magnetic resonance cholangiopancreatography (MRCP) are recommended.
- Individuals with the following conditions are also at an increased risk of pancreatic cancer:[3]
- Hereditary pancreatitis
- Familial pancreatic cancer
- Peutz-Jeghers disease
- Familial atypical mole melanoma syndrome (FAMMM)
- Cystic fibrosis of pancreas,
- Familial cancer syndromes such as:
- Lynch syndrome
- Familial adenomatous polyposis (FAP)
- von Hippel-Lindau syndrome
- Multiple endocrine neoplasia type 1
- Hereditary breast and ovarian cancer-BRCA1 and BRCA2 mutations
References
- ↑ Poruk KE, Firpo MA, Adler DG, Mulvihill SJ (2013). "Screening for pancreatic cancer: why, how, and who?". Ann Surg. 257 (1): 17–26. doi:10.1097/SLA.0b013e31825ffbfb. PMC 4113008. PMID 22895395.
- ↑ Greer JB, Brand RE (2007). "Screening for pancreatic cancer: current evidence and future directions". Gastroenterol Hepatol (N Y). 3 (12): 929–38. PMC 3104195. PMID 21960811.
- ↑ Goral V (2015). "Pancreatic Cancer: Pathogenesis and Diagnosis". Asian Pac J Cancer Prev. 16 (14): 5619–24. PMID 26320426.